Carrier‐free nanodrugs composed of photosensitizer Verteporfin and mammalian target of rapamycin inhibitor Torin 1 are designed for breast cancer treatment with improved photodynamic therapy and tumor microenvironment reshaping effects. Here, MTOR is linked to breast carcinoma.